

Fabrication and Characterization of Lornoxicam Loaded Microsponge Tablets for Colon Delivery

Harshala M Chachare, Neha S Pawar and Vivekanand K Chatap*

Post Graduate Department of Pharmaceutics, H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India

*Corresponding Author: Vivekanand K Chatap, Assistant Professor, Post Graduate Department of Pharmaceutics, H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.


Received: August 27, 2018; Published: September 06, 2018

Abstract

In present investigation first attempt was made to developed lornoxicam (LXM) loaded microsponges prepared by quasi emulsion solvent diffusion technique, by using ethyl cellulose in different concentrations. Microsponges were evaluated for percentage yield, encapsulation efficiency, drug content, surface morphology. Optimized batch of microsponges was further formulated as tablet for colon delivery. In-vitro dissolution study of tablets was performed under sink condition with and without caecal contents. Microsponge tablet showed drug release after 8th hour corresponding to the arrival time in proximal colon and drug release of 81.28% up to 24 hrs. From this study, it can be concluded that, microsponges is an advance combined approach of both the triggering mechanism of microflora-activation and avoiding release in the small intestine.

Keywords: Lornoxicam; Microsponge; Quasi Emulsion Solvent Diffusion Technique and Microsponge Tablet

Graphical Abstract



Figure

Introduction

A colon-targeted drug delivery system should avoid drug release in the upper GI tract and influence a sudden beginning of drug release after going into the colon [1]. Colon as a site for drug delivery offers a few advantages like a close neutral pH, longer transit time, lessened stomach related enzymatic action and a considerably more prominent responsiveness to absorption enhance [2-4]. Colon targeted drug delivery systems increasing interest due to the importance of this area of the gastrointestinal tract, not only for local but also for systemic therapy. Additionally, colonic delivery of drugs may be extremely useful when a delay in drug absorption is needed from a therapeutic standpoint, e.g. in case of diurnal asthma, angina pectoris and arthritis [5,6]. Lornoxicam is a non-steroidal anti-inflammatory drug (Figure 1) utilized in rheumatoid arthritis. It shows different pH dependent solubility, it is very poor soluble in acidic conditions present in the stomach thus it remains in contact with the stomach wall for a long period which might lead to local irritation and ulceration. Half-life of LXM is 3 to 5 hours which increases dosing frequency of the drug and it leads to side effects. Colon is attracting site to deliver lornoxicam systemically to attain good therapeutic effect [7,8]. To avoid such problems we focus on a novel approach to design a microsponge based colon specific tablet formulation. Microsponges are porous microspheres which have small sponge like spherical shape that consist of a numerous interconnecting spaces within a non-collapsible structure with a large porous surface. The proposed study involves preparation and characterization of lornoxicam loaded microsponges by quasi emulsion solvent diffusion technique with ethyl cellulose as a pore forming sustained release polymer and study the effect of drug: polymer ratio, effect of inner phase solvent amount, effect of stirring time and stirring speed on microsponges, finally the optimized microsponge formulation was compressed in to core tablet, then compressed these core tablets with coating of guar gum and HPMC for formulation of mechanically strong colon specific tablet. *In-vitro* dissolution studies were performed with and without addition of caecal




Figure 1: Structure of Lornoxicam.

Materials and Methods

Lornoxicam (LXM) was generously gifted by F & D, Glenmark Pharmaceuticals Ltd, Satpur, Nasik. Ethyl Cellulose, Guar Gum, Starch were purchased from Loba Chemie, Mumbai, Methocel®K4MCR Premium EP, Poly vinyl alcohol was purchased from RFCL Limited, New Delhi, Microcrystalline cellulose, sodium starch glycolate were purchased from Merck specialties Pvt. Ltd, Mumbai, India.

Preparation of Microsponges

Lornoxicam loaded microsponges were prepared by quasi emulsion solvent diffusion technique. In this method, Outer phase was prepared by dissolving polyvinyl alcohol in warm distilled water with continuous stirring at 200 rpm and inner phase was prepared by dissolving ethyl cellulose and drug in solvents like dichloromethane and methanol (4:1 ratio), with constant stirring, Then added 0.1% of dibutyl Phthalate as plasticizer to produce plasticity in microsponges. Composition of microsponges are given in table 1. Then inner phase was incorporated drop wise into outer phase with constant stirring at 500 - 1000 rpm for 12 hours to remove and diffuse dichloromethane and methanol completely from reaction vessel, the mixture was centrifuged at 3000 rpm for 30 minutes and separated microsponges were dried in oven at 40°C for 12 hours [9-11].

Ingredients	CL1	CL2	CL3	CL4	CL5	CL6	CL7
Lornoxicam (mg)	300	400	500	600	900	1000	1100
Ethyl cellulose (mg)*	100	100	100	100	100	100	100
Dichloromethane (ml)* (ml)*	3	3	3	3	3	3	3
Methanol (ml)*	2	2	2	2	2	2	2
Di-butyl Phthalate (ml)*	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Polyvinyl Chloride (mg)* *(mg)* Chloride alcohol	50	50	50	50	50	50	50
Distilled water (ml) *	200	200	200	200	200	200	200

Table 1: Formulation of microsponges.

*values were kept constant

Optimization of formulation and process variables of microsponges preparation

Effect of drug: polymer ratio

The different drug to polymer ratios (LXM:Ethyl cellulose) 3:1, 4:1, 5:1, 6:1, 9:1, 10:1 and 11:1 were taken for the fabrication of different microsponge formulations, during study other parameters like amount of polymer, PVA, Dibutyl phthalate, inner phase solvent etc. were kept constant [12].

Effect of inner phase solvent amount

The inner phase solvent dichloromethane and methanol was selected on the basis of maximum solubility of drug and polymer. LXM was partially soluble in methanol so that, we selected the ratios of dichloromethane and methanol to make it soluble under stirring at 200 rpm, during preparation all other parameters were kept constant [13].

Effect of stirring speed

The effect of stirring speed on the particle size and production yield of microsponges was studied at stirring speed 500 and 1000 rpm. All other parameters were kept constant [13].

Characterization of Microsponges

Fourier transforms infrared (FTIR) analysis

Infrared spectra of Drug, Polymer and formulation CL1, CL2, CL3 were taken by using FT-IR spectrophotometer (IR Infinity, Shimadzu). IR spectrum was measured in the solid state as potassium bromide disk pellet method. The spectra were measured over the range of 4000 - 400 cm^{-1} with an instrument resolution of 4 cm^{-1} [14].

Morphology and particle size studies

Particle size analysis of LXM loaded microsponges were performed by using Malvern Master sizer (Malvern Instruments, Master sizer 2000, and UK). The values (d_{50}) were expressed for all formulations as mean size range. LXM microsponges were coated with gold-palladium under argon atmosphere at room temperature and studied the morphology and surface characteristics by using scanning electron microscopy (SEM, JEOL JXA 840A, USA) [15].

Actual drug content and encapsulation efficiency

The Weighed amount of LXM loaded Microsponges (10 mg) were dissolved in 10 ml 0.1 N NaOH with continuous stirring for 24 hours at 30°C. The samples were filtered by using 0.2 membrane filter and analyzed at 376 nm against blank using UV-spectrophotometer. The actual drug content and encapsulation

efficiency were calculated by using the following formulas. All analyses were carried out in triplicate [16].

$$\text{Actual drug content (\%)} = \frac{(\text{M act})}{(\text{Mms})} \times 100$$

$$\text{Encapsulation efficiency (\%)} = \frac{(\text{M act})}{(\text{M the})} \times 100$$

Where:

Mact is the actual lornoxicam content in weighed quantity of Microsponge,

Mms is the weighed quantity of powder of Microsponge,

Mthe is the theoretical amount of lornoxicam in Microsponge calculated from the quantity added in the process.

In vitro Drug Release of Microsponges

The *in-vitro* drug release of lornoxicam loaded microsponge batches (CL1-CL7) were carried out using USP type II dissolution test apparatus-TDT-06T (Electrolab, Mumbai, India) at 100 rpm. The dissolution study was conducted in 900 ml of 0.1N HCl having pH 1.2 for 2 hours followed by phosphate buffer pH 6.8 for 14 hours at 37°C \pm 0.5°C. A 5 ml aliquot of dissolution medium was withdrawn at 0 - 1 hour with a pipette and filter through 0.45 μm Whatman filter and then analyzed lornoxicam content in triplicate by spectrophotometrically (UV/Vis Spectrophotometer, Shimadzu-1800) at λ_{max} 376 nm. Fresh medium (5 ml), which was prewarmed at 37°C, was replaced immediately into the dissolution medium after each sampling to maintain its constant volume during the test [17].

Rheological Properties of Microsponges

The flowability of the prepared microsponges was determined by measuring their angle of repose, hausner's ratio and Compressibility index [18].

Preparation of Microsponge Core Tablet

The core tablets containing LXM loaded microsponges (Equivalent to 8 mg LXM), sodium starch glycolate, microcrystalline cellulose, talc and magnesium stearate were prepared by direct compression method. The composition of core tablets are given in table 2. All tablet ingredients were accurately weighed and mixed properly, after mixing tablets were compressed by using 12 station multi-punch tooling, Mini Press-II Tablet Machine (Karnawati, Ahmedabad) [12].

Ingredient	Microsponge formulation (equivalent to 8 mg lornoxicam)			Sodium starch Glycolate	MCC	Talc	Mg. stearate
	CL1	CL2	CL3				
CLC1	9.98	-	-	5	84.02	0.5	0.5
CLC2	-	9.79	-	5	84.21	0.5	0.5
CLC3	-	-	10.12	5	83.88	0.5	0.5

Table 2: Formulation of Core Tablet.

CLC1, CLC2 and CLC3 indicate core tablets containing CL1, CL2 and CL3 microsponge formulations respectively.

Coating of Colon Targeted Tablets

The optimized LXM Microsponge core tablets were coated by taking different ratios of Guar Gum and HPMC. The composition of coat of tablets are given in table 3. The coating mixture used was 200 mg. Fifty percent, that is 100 mg coating material was placed in the die cavity and the core tablet was placed in center, then added remaining mixture of coat in the die cavity and compressed at high pressure using round concave punches (12.6 mm) on electric, semi-automatic, 12 station multi-punch tooling, Mini Press-II Tablet Machine (Karnawati, Ahmedabad) [16].

Ingredients	Coated Formulation		
	CT60	CT70	CT80
Guar gum	60	70	80
HPMC K4M	40	30	20
Starch paste	10	10	10

Table 3: Composition of Coat of Tablets.

Evaluation of Coated and Uncoated Tablets

The LXM loaded microsponges coated and uncoated tablets were evaluated for their friability (By Roche friabilator), hardness (By Monsanto hardness tester), thickness (By vernier calipers), weight variations and drug content [19].

Determination of *in-vitro* transit time

In-vitro transit time were determined by placing tablets (n = 6) in tablet disintegration test apparatus USP and subjected to regular up and down movement in a series of gastrointestinal fluids at 30 ± 2 cpm. The sequence followed was exposure to simulated gastric fluid (SGF, pH 1.2) for initial 2 hours followed by simulated intestinal fluid (SIF, pH 7.4) for the next 6 hours at 37 ± 0.50C. The tablets were visually observed for any damage and disintegration.

Preparation of caecal contents for *in-vitro* drug release studies

The susceptibility of guar gum coats to the enzymatic action of colonic bacteria which shows microbial triggered release mechanism followed by microflora-activation for caecal contents were prepared by administered 1 ml of 2% w/v aqueous dispersion of guar gum in male albino rats pre-treatment for 7 days. Make a plan before 1 hour drug release studies to isolate caecal content by killing six albino rat by spinal traction. The cecal bag were isolated after opening abdomen of rat, then transferred individually weighed caecal content give a final concentration 4% w/v. as caecum is naturally anaerobic into previously bubbled with CO₂ pH 6.8 phosphate buffer solution and all this operation were carried out under continuous bubbled with CO₂ [20-22].

In-vitro Drug Release Studies

The *in-vitro* drug release study of compressed LXM loaded Microsponge core coated tablet formulations was carried out by USP type II (paddle) apparatus (TDT-06T, Electrolab, Mumbai, India at 100 rpm at 37°C ± 0.5°C) in different dissolution media. The drug release studies were carried out for 24 hours and samples were withdrawn periodically and sink conditions were maintained by replacing with equal amount of fresh pre-warmed dissolution medium. The dissolution study was performed using 900 ml 0.1 N HCl having pH 1.2 for 2 hours, followed by pH 7.4 Sorensen's Phosphate buffer (900 ml) for 3 hours. Drug release was continued for 24 hours in Sorensen's Phosphate buffer containing 4% w/v rat caecal matter under anaerobic condition. After 24 hours, samples were analyzed by spectrophotometrically (UV/Vis Spectrophotometer, Shimadzu-1800) at λ_{max} 376 nm [23,24].

Results and Discussion

Optimization of Formulation and Process Variables of Microsponges Preparation

The formulation parameters were optimized on the basis of surface morphology, particle size, actual drug content, encapsulation efficiency and drug release of Microsponges. The optimized parameters are given in table 5. It was observed as drug to polymer ratio increased from 3:1 to 5:1 there was decreased particle size from 109 to 88 μm. The production yield, actual drug content, encapsulation efficiency of microsponge formulations were 93.75 to 76.75%, 82.41 to 75.34% and 96.66

to 84.66% respectively, as given in table 4. After complete drying of prepared microsponges, it was subjected to weighing, the weight of microsponges after 3 hours stirring was more than 6 hours and 8 hours. This indicated that there was presence of organic solvent in the microsponges prepared at 3 hours and 6 hours, as a result 8 hours stirring time was investigated as optimized stirring time. If stirring speed decreased the fibrous and coarse particles are prepared. It was observed that as concentration of plasticizer increases, drying rate of microsponges were also increases. Optimized formulation parameters of lornoxicam loaded Microsponges are given in Table 4.

Formulation code	LXM:EC Ratio	Production yield (%)	Theoretical drug content (%)	Actual drug Content (%)	Encapsulation Efficiency (%)	Mean particle size (μm)
CL1	3:1	93.75	95.27	82.41	96.66	109
CL2	4:1	91.66	90.21	77.33	90.63	98
CL3	5:1	76.75	88.23	75.34	84.66	88

Table 4: Production yield, encapsulation efficiency, mean particle size, actual drug content of formulation.

Specification	Optimum values
Lornoxicam: ethyl cellulose ratio	3:1, 4:1 and 5:1
Amount of emulsifying agent (mg)	PVA (Polyvinyl alcohol) 50 mg
Inner phase solvent (ml)	Dichloromethane and Methanol ratio. 4:1
Plasticizer	Dibutyl phthalate
Amount of plasticizer	0.01 ml
Amount of inner phase solvent (ml)	5 ml
Amount of water in the outer phase (ml)	200 ml
Stirring rate (rpm)	1000
Stirring time (Hours)	8

Table 5: Optimized formulation Parameter of Microsponge.

In-vitro Drug Release of Microsponges

The drug release profiles obtained from formulations CL1 to CL7 are depicted in figure 2. The release showed a bi phasic pattern with an initial burst effect. The formulations CL1, CL2 and CL3 showed more control release action than CL4, CL5, CL6 and CL7. At the end of 8 hours, the percent drug release shown by formulations CL1, CL2, CL3 was 85.80%, 92.41% and 96% respectively and for formulations CL4 to CL7 showed 100% release in 5 - 7 hours respectively.




Figure 2: In -Vitro Drug release of Microsponge formulation (data represent mean ± standard deviation, n = 3).

Characterization of Microsponges

Pre-compression Parameters

Pre-compression Parameters of microsponges such as angle of repose, bulk density, tapped density, Hausner's ratio and compressibility index were studied. The Hausner's ratio and compressibility index were found to be 1.16 ± 0.02 to 1.25 ± 0.01 and 14.1 ± 1.7 to 20.5 ± 0.9 . The bulk density and tapped density were found in the range of 0.53 to 0.56 and 0.60 to 0.71. The angle of repose was found in the range of 19.66 ± 0.57 to 28.33 ± 1.52 it indicates that microsponges have good flow property. The results are represented in Table 6.

Formulation Code	Parameter				
	Angle of Repose (θ)	Bulk Density (gm/cm ³)	Tapped Density (gm/cm ³)	Hausner's Ratio (HR)	Compressibility Index (%)
CL1	19.66 ± 0.57	0.53	0.60	1.16 ± 0.02	14.1 ± 1.7
CL2	21 ± 0.57	0.54	0.62	1.24 ± 0.01	19.4 ± 0.7
CL3	21.33 ± 0.55	0.55	0.63	1.25 ± 0.01	20.5 ± 0.9
CL4	23.33 ± 0.577	0.55	0.66	1.17 ± 0.009	15.1 ± 0.6
CL5	25 ± 1	0.56	0.67	1.17 ± 0.02	14.8 ± 1.6
CL6	25.66 ± 1.52	0.56	0.69	1.21 ± 0.03	17.8 ± 2.1
CL7	28.33 ± 1.52	0.54	0.71	1.17 ± 0.04	14.4 ± 2.9

Table 6: Pre-compression Parameter of Microsponges.

Morphology

The morphology and structure of LXM loaded microsponge samples were examined using a scanning electron microscope. The representative SEM images of the microsponges are shown in figure 3, 4 and 5 respectively. Microsponges presented in SEM images are porous but not spherical.




Figure 3: SEM of CL1.




Figure 4: SEM of CL2.




Figure 5: SEM of CL3.

Fourier Transforms Infrared (FT-IR) Analysis

Figure 6 represents FTIR spectra of lornoxicam, ethyl cellulose, and formulation batches (from CL1 to CL3). The FT-IR spectrum of lornoxicam showed a characteristic peak at 3090 cm⁻¹ corresponding to -NH stretching vibration. Intense absorption peak was found at 1642 cm⁻¹ due to the stretching vibration of the C = O group in the primary amide. Other peaks were observed at 1597 and 1559 cm⁻¹ which were assigned to bending vibrations of the N-H group in the secondary amide. The stretching vibrations of the O=S=O group appeared at 1157, 1387, and 1336 cm⁻¹. Other prominent peaks appeared at 827.94 cm⁻¹ corresponding to -CH aromatic ring bending and heteroaromatics and others appeared at 766.8 cm⁻¹ due to the C-Cl bending vibration. The spectrum of ethyl cellulose shows characteristic absorption bands for -C-O-C- stretching vibration at 1052 cm⁻¹ and C-H stretching bands at 2880 cm⁻¹ and 2970 cm⁻¹. The absorption at 1369 cm⁻¹ corresponds to C-H bending. The characteristic peak of drug was found in formulations of microsponges, so it indicates that there is no chemical interaction of drug and polymer.

Evaluation Parameters of Core and Coated Tablets

The core tablets of microsponges containing Lornoxicam (8

mg), sodium starch glycolate, MCC, talc and magnesium stearate were prepared by direct compression method. The core tablets were evaluated for the drug content, friability, thickness and hardness. The mean drug content of core tablet was found to be 95 - 98%. The hardness of tablets were found in range between 3.5 - 4.1 kg/cm². Thicknesses of tablets were found to be 3.5 - 3.75 mm (diameter 6.33 mm). The friability was found in range of 0.31 to 0.51. The results are given in Table 7.




Figure 6: FT-IR of Drug, ethyl cellulose and formulation.

Formulation code	Hardness	Friability	Thickness	Drug content
CLC1	3.5 kg/cm ²	0.34	3.5	95
CLC2	4.1 kg/cm ²	0.31	3.75	97
CLC3	4.0 kg/cm ²	0.51	3.75	98

Table 7: Post compression parameters of core tablets.

The compression coated tablet was prepared by taking different concentrations of guar gum and HPMC K4M. The composition of coat is given in table 3. The batches of microsponges (CL1, CL2 and CL3 containing 3:1, 4:1 and 5:1 drug to polymer ratio respectively) were compressed with gaur gum and HPMC K4M using high compression force, having hardness of 4 to 5 kg/cm². Thickness was found to be 4.34 mm (diameter 10.34 mm) (Table 8). The difference in the core and coated tablet was 6 mm. This indicated that, the 3.00 mm guar gum coat was applied over the core of the tablet. The friability was found in range of 0.31 - 0.54 which indicating satisfactory mechanical strength. The results are shown in table 8.

Formulation code	Hardness	Friability	Thickness
CT60,3	4 kg/cm ²	0.34	4.34
CT60,4	4 kg/cm ²	0.31	4.34
CT60,5	5 kg/cm ²	0.51	4.34
CT70,3	4 kg/cm ²	0.48	4.34
CT70,4	4 kg/cm ²	0.54	4.34
CT70,5	5 kg/cm ²	0.53	4.34
CT80,3	5 kg/cm ²	0.43	4.34
CT80,4	4 kg/cm ²	0.45	4.34
CT80,5	4 kg/cm ²	0.52	4.34

Table 8: Post compression parameter of coated tablet formulation.

In Vitro Gastric Transit Time

Tablets were evaluated for in vitro gastric transit time, all tablets were subjected to the disintegration apparatus. Each tablet showed resistance to disintegration during its passage from stomach to intestine.

In vitro Release of Compression Coated Tablet

The developed formulations CT 60, CT 70, CT 80 were subjected to *in vitro* dissolution study. It was observed that drug was not released in first 5 hour of dissolution study. This indicated that compression coating of guar gum formulation avoids drug release in the physiological pH of stomach and Small intestine. The dissolution studies of three formulation coating mixtures were carried out in simulated stomach fluid having pH 1.2 followed by simulated intestinal fluid having pH 7.4 Sorensen’s Phosphate buffer; after 5 hours lag period dissolution media changed with 4% rat caecal content. The percent drug release of formulation batches CT 60, CT 70, CT 80 (having 3:1 drug to polymer ratio) was found to be 66.94, 58.50 & 48.94%, The percent drug release of formulated batches CT 60, CT 70, CT 80 (having 4:1 drug to polymer ratio) was found to be 78.1953, 64.13 and 57.38%, and percent drug release of formulation batches CT 60, CT 70, CT 80 (having 5:1 drug to polymer ratio) was found to be 81.28, 70.31 and 59.91% respectively. The results are depicted in figure 7. Comparative study of all formulation showed that, as guar gum coat concentration increased with decreased drug release of formulations. The percent drug release (without caecal content) for formulated CT80 batches (having drug to polymer ratio 3:1, 4:1, 5:1) was found to be 48.94%, 57.36% and 59.91%. The percent drug release for formu-

lated CT70 batches (having drug to polymer ratio 3:1, 4:1, 5:1) was found to be 58.50%, 64.13% and 70.31%. The percent drug release for formulated CT60 batches (having drug to polymer ratio 3:1, 4:1, 5:1) was found to be 66.94%, 78.1953% and 81.28%. The results are illustrated in figure 8. From the result compression coated formulation CT 60 shows drug release above 60% using minimum concentration of guar gum in 24 hours study. The *in-vitro* dissolution study of formulations CT 60, CT 70 and CT 80 (having drug to polymer ratio 5:1, 4:1 and 3:1) were performed without rat caecal content. From this study it was observed that, the drug release increased in the presence of 4% rat caecal content.




Figure 7: Comparative study of 3:1, 4:1 and 5:1 (i.e. CL1, CL2 and CL3 microsponge batches) compression coated tablets with rat caecal content (data represent mean ± standard deviation, n = 3).




Figure 8: Drug release of the compression coated formulation without rat caecal content (data represent mean ± standard deviation, n = 3).

Conclusion

Lornoxicam loaded microsponges were prepared by quasi emulsion solvent diffusion technique, further colon targeted tablets were prepared by direct compression method and coating was done using different concentrations of gaur gum and HPMCK4M. All the colon specific tablets were evaluated for drug content, *in-vitro* dissolution study, friability, thickness, hardness were found to be within pharmacopoeial limits. The susceptibility of the prepared tablets to the enzymatic action of colonic bacteria was examined by performing the drug release in medium containing rat caecal material (4%). From the *in-vitro* dissolution studies it was found to be that formulation CT 60,5 with 60:40 ratio of guar gum and HPMCK4M coating material was observed to be the best because, it shows the best appearance, friability, hardness and extreme percentage drug release of 81.28% with rat caecal content at the end of 24 hours in *in-vitro* dissolution studies. In the present work, the colon targeted tablet formulation containing guar gum and HPMCK4M 60:40 as a coating is most likely to target drug to colon.

Acknowledgment

The authors are grateful to Glenmark Pharmaceuticals Ltd. (Satpur, Nasik) for providing gift sample of lornoxicam. They are also grateful to the H. R. Patel Institute of Pharmaceutical Education and Research for providing all the necessary facilities and infrastructure to carry out this study.

Bibliography

1. Comoglu T., *et al.* "The effects of pressure and direct compression on tableting of microsponges". *International Journal of Pharmaceutics* 242.1-2 (2002): 191-195.
2. Davis SS., *et al.* "Overcoming barriers to the oral administration of peptide drugs". *Trends in Pharmacological Sciences* 11.9 (1990): 353-355.
3. Digenis GA., *et al.* "Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms". *Critical Reviews in Therapeutic Drug Carrier Systems* 7.4 (1991): 309-345.
4. Jain V and Singh R. "Development and characterization of eudragit RS 100 loaded microsponges and its colonic delivery using natural polysaccharides". *Acta Poloniae Pharmaceutica Drug Research* 67.4 (2010): 407-415.
5. Kawashima Y., *et al.* "Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method". *Journal of Pharmaceutical Sciences* 78.1 (1989): 68-72.

6. Kinget R., *et al.* "A review: Colonic drug targeting". *Journal of Drug Targeting* 6.2 (1998): 129-149.
7. Krishnaiah YS., *et al.* "In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil". *European Journal of Pharmaceutical Sciences* 16.3 (2002): 185-192.
8. Drakopoulou S., *et al.* "Effects of Lornoxicam on Anastomotic Healing: A Randomized, Blinded, Placebo-Control Experimental Study". *Surgery Research and Practice* (2016): 4328089.
9. Karthika R., *et al.* "Formulation and evaluation of lornoxicam microsponges tablets for the treatment of arthritis". *International Journal of Pharmaceutical Innovations* 3.2 (2013): 29-40.
10. Osmani RA., *et al.* "Microsponge based drug delivery system for augmented gastroparesis therapy: Formulation development and evaluation". *Asian Journal of Pharmaceutical Sciences* 10.5 (2015) : 442-451.
11. Mutha RE., *et al.* "Formulation and evaluation of sertaconazole nitrate microsponge gel". *Inventi Rapid: NDDS* 3 (2018): 1-7.
12. Kumari A., *et al.* "Eudragit S100 coated microsponges for Colon targeting of prednisolone". *Drug Development and Industrial Pharmacy* 44.6 (2018): 902-913.
13. Jain V and Singh R. "Dicyclomine-loaded Eudragit®-based microsponge with potential for colonic delivery: preparation and characterization". *Tropical Journal of Pharmaceutical Research* 9.1 (2010): 67-72.
14. Rekha U and Manjula BP. "Formulation and evaluation of microsponges for topical drug delivery of mometasone furoate". *International Journal of Pharmacy and Pharmaceutical Sciences* 3.4 (2011): 133-137.
15. Abdelmalak NS and El-Menshawe SF. "A new topical fluconazole microsponge loaded hydrogel: Preparation and characterization". *International Journal of Pharmacy and Pharmaceutical Sciences* 4.1 (2012): 460-468.
16. Mishra MK., *et al.* "Optimization, formulation development and characterization of Eudragit RS 100 loaded microsponges and subsequent colonic delivery". *International Journal of Drug Discovery and Herbal Research* 1.1 (2011): 8-13.
17. Singh R. "Formulation and evaluation of colon targeted drug delivery system". *International Journal of Pharmacy and Life Sciences* 3.12 (2012): 2265-2268.
18. Rao YS., *et al.* "Formulation and in vitro evaluation of colon targeted matrix tablets of mebeverine hydrochloride using natural polymers". *Journal of Pharmacy Research* 8.11 (2014): 1682-1689.
19. Rajeswari P., *et al.* "Formulation and characterization of colon specific drug delivery system of matrix tablet". *World Journal of Pharmaceutical Sciences* 2.2 (2016): 330-348.
20. Orlu M., *et al.* "Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges". *International Journal of Pharmaceutics* 318.1-2 (2006): 103-117.
21. Sareen R., *et al.* "Curcumin loaded microsponges for colon targeting in inflammatory bowel disease: fabrication, optimization, and in vitro and pharmacodynamic evaluation". *Biomed Research International* (2014): 340701.
22. Gandhi SD., *et al.* "Design, formulation and evaluation of a colon specific drug delivery system for a model anthelmintic drug-ivermectin". *Journal of Chemical and Pharmaceutical Research* 2.5 (2010): 229-243.
23. Mehmood Y., *et al.* "Formulation and In-vitro Evaluation of Ileo-Colonic Targeted Tablet of Flurbiprofen Using Natural and Semi Synthetic Polymers for Ulcerative Colitis". *Journal of Advances in Medical and Pharmaceutical Sciences* 9.1 (2016): 1-12.
24. Vemula SK and Veerareddy PR. "Colon specific controlled release matrix tablets of flurbiprofen: development and characterization". *Asian Journal of Pharmaceutical and Clinical Research* 5.4 (2012): 92-96.

Volume 2 Issue 10 October 2018

© All rights are reserved by Vivekanand K Chatap., et al.